Natural Compound Miliusin B Kills and Blocks Migration of HeLa Cervical Cancer Cells

A natural neolignan called Miliusin B has shown selective cytotoxic and anti-migratory activity against HeLa cervical cancer cells in laboratory experiments, according to a study published in Medical Oncology on 20 October 2026. The compound, originally isolated from the plant Miliusa sessilis, killed HeLa cells at sub-micromolar concentrations while showing more than 60-fold selectivity relative to non-cancerous control cells.

The work builds on the research team’s earlier report, which described the discovery, chemical characterization, and preliminary anticancer activity of Miliusin B, including its cytotoxicity against the HeLa cell line. In the new study, the investigators probed the mechanisms behind that activity. They found that at a cytotoxic concentration of 5 micromolar, Miliusin B arrested HeLa cells in the G2/M phase of the cell cycle and activated apoptotic cell death pathways. Evidence for apoptosis came from the cleavage of caspase-9, caspase-3, and PARP, a molecular signature indicating that the cells were executing the programmed death process rather than dying nonspecifically.

Beyond its killing effect at higher doses, the compound interfered with cancer cell behavior at concentrations too low to be toxic. Miliusin B significantly impaired HeLa cell migration at sub-toxic concentrations of 0.5 micromolar or less, suggesting it may affect processes involved in the spread of cancer cells, at least in this laboratory model.

In a three-dimensional spheroid model, Miliusin B suppressed spheroid growth at both 0.5 and 5 micromolar, extending the two-dimensional findings into a more tissue-like setting.

Finally, the researchers examined whether Miliusin B could complement existing cervical cancer chemotherapy. In combination assays with cisplatin-based regimens, including cisplatin alone and cisplatin doublet treatments, the compound enhanced the anti-proliferative effects of every regimen tested. The authors conclude that these findings position Miliusin B as a promising selective cytotoxic and anti-migratory candidate for further development as a potential therapeutic agent against cervical cancer.

It is important to note the scope of this evidence. All of the reported results come from cell culture experiments using the HeLa cell line and spheroid models, and the abstract does not report data from animal studies or human trials. Whether Miliusin B reaches tumors in a living body, what doses would be tolerable, and how it behaves alongside chemotherapy in patients remain open questions that would require further preclinical and clinical testing. The authors themselves frame the compound as a candidate for further development rather than a validated treatment. Nevertheless, the combination of sub-micromolar potency, high selectivity for cancerous over non-cancerous cells, mechanistic evidence of apoptosis, anti-migratory activity at low doses, and enhancement of standard cisplatin-based regimens presents a coherent early-stage case for continued investigation of this plant-derived neolignan in cervical cancer research.

Subject of Research: Mechanisms of the natural neolignan Miliusin B as a selective cytotoxic and anti-migratory agent against HeLa cervical cancer cells

Article Title: The neolignan Miliusin B inhibits cell migration and promotes apoptotic cell death in cervical cancer cell line HeLa

Article References: Srisuphan, R., Rayanil, K.-O., Pengnam, S., Wongprayoon, P., & Charoensuksai, P. (2026). The neolignan Miliusin B inhibits cell migration and promotes apoptotic cell death in cervical cancer cell line HeLa. Medical Oncology, 43(11), Article 347. https://doi.org/10.1007/s12032-026-03457-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03457-6

Keywords: Miliusin B, neolignan, Miliusa sessilis, cervical cancer, HeLa cells, apoptosis, cell migration, G2/M cell-cycle arrest, cisplatin, spheroid model, natural products, Medical Oncology